Literature DB >> 15904881

Cardiac rehabilitation reduces the rate of major adverse cardiac events after percutaneous coronary intervention.

Paul Dendale1, Jan Berger, Dominique Hansen, Johan Vaes, Edouard Benit, Maria Weymans.   

Abstract

BACKGROUND: Despite multiple publications on effects of rehabilitation in cardiac patients, rehabilitation is not fully known to be of value in post-percutaneous coronary intervention (PCI) patients. AIMS: To investigate the influence of cardiac rehabilitation on the incidence of major adverse cardiac events (MACEs) in post-PCI patients.
METHODS: Retrospectively and nonrandomized 140 post-PCI patients (107 males, mean age 62 (7) years) participated in a 3-month rehabilitation program, starting 2 weeks post-PCI, while 83 post-PCI patients (54 males, mean age 68 (8) years) did not and were all followed up for 15 months. Data on cardiac medication prescription and incidence of MACE (including angina pectoris with or without reintervention, restenosis, myocardial infarction, revascularisation with re-PCI or CABG, and death) were collected. The relationship with cardiovascular risk factors including sex, smoking behaviour, obesity, diabetes mellitus, hypertension, familiar predisposition, and hypercholesterolemia was analysed.
RESULTS: The incidence of total MACE in the rehabilitation group is significantly lower than in the control group (24% vs. 42%, respectively; P<0.005). The incidence of documented restenosis, angina pectoris with resulting reintervention, all revascularisations, and death is significantly lower in the rehabilitation group, compared with the control group.
CONCLUSION: The incidence of MACE and restenosis is significantly lower when PCI patients are included in a cardiac rehabilitation program.

Entities:  

Mesh:

Year:  2004        PMID: 15904881     DOI: 10.1016/j.ejcnurse.2004.11.003

Source DB:  PubMed          Journal:  Eur J Cardiovasc Nurs        ISSN: 1474-5151            Impact factor:   3.908


  7 in total

1.  [The importance of rehabilitation with cardiovascular diabetic patients after surgical interventions].

Authors:  S Jacob
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

2.  Cardiac Rehabilitation of Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in a Han Population in Northern China: A Prospective Cohort Study.

Authors:  Jingru Ma; Yuling Tai; Mengmeng Fan; Zhansheng Wang
Journal:  Int J Gen Med       Date:  2021-08-28

3.  Retrospective Analysis and Forecasted Economic Impact of a Virtual Cardiac Rehabilitation Program in a Third-Party Payer Environment.

Authors:  Arash Harzand; Aaron C Weidman; Kenneth R Rayl; Adelanwa Adesanya; Ericka Holmstrand; Nicole Fitzpatrick; Harshvardhan Vathsangam; Srinivas Murali
Journal:  Front Digit Health       Date:  2021-11-24

4.  Can cardiac rehabilitation programs improve functional capacity and left ventricular diastolic function in patients with mechanical reperfusion after ST elevation myocardial infarction?: A double-blind clinical trial.

Authors:  Allahyar Golabchi; Fatemeh Basati; Mehdi Kargarfard; Masoumeh Sadeghi
Journal:  ARYA Atheroscler       Date:  2012

5.  Rehabilitation training improves exercise tolerance after percutaneous coronary intervention.

Authors:  Fang Cui; Yusheng Ren; Heng Jin; Bo Cui
Journal:  J Biomed Res       Date:  2012-05-29

6.  Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.

Authors:  Yahya Dadjou; Salar Safavi; Javad Kojuri
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

7.  Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention.

Authors:  Manuel F Jiménez-Navarro; Francisco Lopez-Jimenez; Luis M Pérez-Belmonte; Ryan J Lennon; Carlos Diaz-Melean; J P Rodriguez-Escudero; Kashish Goel; Daniel Crusan; Abhiram Prasad; Ray W Squires; Randal J Thomas
Journal:  J Am Heart Assoc       Date:  2017-10-11       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.